PARIS, December 21 (Reuters) – Stocks to watch Tuesday on the Paris Stock Exchange and in Europe where futures indicate an opening up more than 1%:
* SANOFI announced on Tuesday that it had reached an agreement to acquire Immunix Pharmaceuticals, a company specializing in immuno-oncology, for an initial payment of one billion dollars, marking the latest acquisition of the French group which is active for several months to compensate for the delay in vaccines.
* AIRBUS – Qatar Airways announced on Monday that it has started legal action against Airbus in a UK court in an attempt to resolve a dispute over accelerated wear and tear on the A350 fuselage surface, paving the way for a rare legal battle over the aviation safety.
* ERAMET announced on Tuesday that it had identified a financial fraud within its cash management at the group’s headquarters, and immediately carried out the necessary investigations to put an end to it.
* UBS – The Swiss bank announced Monday that it would appeal against its conviction in France for illicit bank directing and laundering of aggravated tax fraud.
* BOLLORÉ – Vincent Bolloré’s group announced on Monday that it had received an offer from the Swiss MSC, specialist in sea freight, for its transport and logistics activities in Africa on the basis of an enterprise value of 5.7 billion d ‘euros.
* ESSILORLUXOTTICA announced on Tuesday that at the end of the post-acceptance period which ended on December 20, it held approximately 99.84% of the issued shares of the share capital of GRANDVISION, including the last trading session on the Amsterdam Stock Exchange. is set for January 7.
* CASINO and its renewable energies subsidiary GreenYellow announced on Tuesday a strategic collaboration with Amazon Web Services in the fields of energy and cloud computing.
* RENAULT and DASSAULT SYSTÈMES announced Tuesday a strengthening of their partnership to accelerate the transformation of the automobile manufacturer with the 3DEXPERIENCE platform of the design and manufacturing software publisher.
* DBV TECHNOLOGIES announced on Monday that it had officially notified the European Medicines Agency of its decision to withdraw the marketing authorization application for Viaskin Peanut, its flagship experimental treatment for peanut allergy, which was in progress. review by the agency. At the same time, the group announced that it had informed the FDA of its intention to start a new pivotal phase III clinical study of the modified patch Viaskin Peanut in children.
* CARREFOUR and Everli have entered into a partnership for the delivery of online shopping in France and in new markets.
* SMCP announced Tuesday the appointment of Charlotte Tasset Ferrec to the general management of Maje.
* GLAXOSMITHKLINE – The US FDA on Monday approved an injectable form of cabotegravir, developed by the British pharmaceutical company, given every two months to reduce the risk of HIV infection.
* ADIDAS and PUMA gain 2.3% and 3% respectively in pre-market trading in the wake of the American Nike, which took 3.7% after-market Monday on Wall Street, after its superior quarterly results expectations to.
THE FRANCE & INTERNATIONAL 7-DAY AGENDA: (Written by Claude Chendjou and Laetitia Volga, edited by Blandine Hénault)